MiR-205 determines the radioresistance of human nasopharyngeal carcinoma by directly targeting PTEN

Cell Cycle

Volumn 11, Issue 4, 2012, Pages 785-796

  Qu, Changju ^a,b   Liang, Zhihui ^c   Huang, JiaLing ^d   Zhao, Ruiying ^b   Su, Chunhui ^b   Wang, Sumei ^a   Wang, Xudan ^a   Zhang, Rong ^c   Lee, Mong Hong ^b   Yang, Huiling ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

miR 205; miRNA; Nasopharyngeal carcinoma; PTEN; Radioresistance

Indexed keywords

MICRORNA; MIR 205; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATASE AND TENSIN HOMOLOGY; PHOSPHATIDYLINOSITOL 3 KINASE; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER RADIOTHERAPY; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION REGULATION; GENE SILENCING; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MICROARRAY ANALYSIS; NASOPHARYNX CARCINOMA; PREDICTION; PROTEIN EXPRESSION; RADIOSENSITIVITY; SIGNAL TRANSDUCTION; TREATMENT RESPONSE;

EID: 84863116263     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.11.4.19228     Document Type: Article

References (36)

1. Feng XP, Yi H, Li MY, Li XH, Yi B, Zhang PF, et al. Identification of biomarkers for predicting nasopharyngeal carcinoma response to radiotherapy by proteomics. Cancer Res 2010; 70:3450-62; PMID:20406978; http://dx.doi.org/10. 1158/0008-5472.CAN-09-4099.
2. DeNittis AS, Liu L, Rosenthal DI, Machtay M. Nasopharyngeal carcinoma treated with external radiotherapy, brachytherapy and concurrent/ adjuvant chemotherapy. Am J Clin Oncol 2002; 25:93-5; PMID:11823706; http://dx.doi. org/10.1097/00000421-200202000-00020.
3. Chang JT, Ko JY, Hong RL. Recent advances in the treatment of nasopharyngeal carcinoma. J Formos Med Assoc 2004; 103:496-510; PMID:15318271.
4. Mostafa E, Nasar MN, Rabie NA, Ibrahim SA, Barakat HM, Rabie AN. Induction chemotherapy with paclitaxel and cisplatin, followed by concomitant cisplatin and radiotherapy for the treatment of locally advanced nasopharyngeal carcinoma. J Egypt Natl Canc Inst 2006; 18:348-56; PMID:18301458.
5. Gupta AK, McKenna WG, Weber CN, Feldman MD, Goldsmith JD, Mick R, et al. Local recurrence in head and neck cancer: relationship to radiation resistance and signal transduction. Clin Cancer Res 2002; 8:885- 92; PMID:11895923.
6. Qin X, Wang X, Wang Y, Tang Z, Cui Q, Xi J, et al. MicroRNA-19a mediates the suppressive effect of laminar flow on cyclin D1 expression in human umbilical vein endothelial cells. Proc Natl Acad Sci USA 2010; 107:3240-4; PMID:20133739; http://dx.doi. org/10.1073/pnas.0914882107.
7. Radojicic J, Zaravinos A, Vrekoussis T, Kafousi M, Spandidos DA, Stathopoulos EN. MicroRNA expression analysis in triple-negative (ER, PR and Her2/neu) breast cancer. Cell Cycle 2011; 10:507- 17; PMID:21270527; http://dx.doi.org/10.4161/ cc.10.3.14754.
8. Zhang L, Deng T, Li X, Liu H, Zhou H, Ma J, et al. microRNA-141 is involved in a nasopharyngeal carcinoma-related genes network. Carcinogenesis 2010; 31:559-66; PMID:20053927; http://dx.doi. org/10.1093/carcin/bgp335.
9. Alajez NM, Lenarduzzi M, Ito E, Hui AB, Shi W, Bruce J, et al. MiR-218 suppresses nasopharyngeal cancer progression through downregulation of survivin and the SLIT2-ROBO1 pathway. Cancer Res 2011; 71:2381-91; PMID:21385904; http://dx.doi. org/10.1158/0008-5472.CAN-10-2754.
10. Lu J, He ML, Wang L, Chen Y, Liu X, Dong Q, et al. MiR-26a inhibits cell growth and tumorigenesis of nasopharyngeal carcinoma through repression of EZH2. Cancer Res 2011; 71:225-33; PMID:21199804; http://dx.doi.org/10.1158/0008-5472. CAN-10-1850.
11. Sengupta S, den Boon JA, Chen IH, Newton MA, Stanhope SA, Cheng YJ, et al. MicroRNA 29c is downregulated in nasopharyngeal carcinomas, upregulating mRNAs encoding extracellular matrix proteins. Proc Natl Acad Sci USA 2008; 105:5874- 8; PMID:18390668; http://dx.doi.org/10.1073/ pnas.0801130105.
12. Takamizawa J, Konishi H, Yanagisawa K, Tomida S, Osada H, Endoh H, et al. Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res 2004; 64:3753-6; PMID:15172979; http://dx.doi. org/10.1158/0008-5472.CAN-04-0637.
13. Weidhaas JB, Babar I, Nallur SM, Trang P, Roush S, Boehm M, et al. MicroRNAs as potential agents to alter resistance to cytotoxic anticancer therapy. Cancer Res 2007; 67:11111-6; PMID:18056433; http://dx.doi. org/10.1158/0008-5472.CAN-07-2858.
14. Wang X, Yang H, Guo Y, Liang Z, Zhao R, Xia Y, et al. Discrepancy of microRNA in different radio-resistant nasopharyngeal carcinoma cells. Chinese Journal of Pathophysiology 2007; 23:1045-8.
15. Lee JJ, Kim BC, Park MJ, Lee YS, Kim YN, Lee BL, et al. PTEN status switches cell fate between premature senescence and apoptosis in glioma exposed to ionizing radiation. Cell Death Differ 2011; 18:666- 77; PMID:21072054; http://dx.doi.org/10.1038/ cdd.2010.139.
16. Park JK, Jung HY, Park SH, Kang SY, Yi MR, Um HD, et al. Combination of PTEN and gamma-ionizing radiation enhances cell death and G(2)/M arrest through regulation of AKT activity and p21 induction in non-small-cell lung cancer cells. Int J Radiat Oncol Biol Phys 2008; 70:1552-60; PMID:18374229; http:// dx.doi.org/10.1016/j.ijrobp.2007.11.069.
17. Cheng JJ, Hu Z, Xia YF, Chen ZP. Radio-resistant subline of human glioma cell line MGR2R induced by repeated high dose X-ray irradiation. Ai Zheng 2006; 25:45-50; PMID:16405748.
18. Virsik-Köpp P, Hofman-Hüther H, Rave-Fränk M, Schmidberger H. The effect of wortmannin on radiation- induced chromosome aberration formation in the radio-resistant tumor cell line WiDr. Radiat Res 2005; 164:148-56; PMID:16138421; http://dx.doi. org/10.1667/RR3396.1.
19. Lee HC, Kim DW, Jung KY, Park IC, Park MJ, Kim MS, et al. Increased expression of antioxidant enzymes in radio-resistant variant from U251 human glioblastoma cell line. Int J Mol Med 2004; 13:883-7; PMID:15138630.
20. Henness S, Davey MW, Harvie RM, Davey RA. Fractionated irradiation of H69 small-cell lung cancer cells causes stable radiation and drug resistance with increased MRP1, MRP2 and topoisomerase IIalpha expression. Int J Radiat Oncol Biol Phys 2002; 54:895- 902; PMID:12377343; http://dx.doi.org/10.1016/ S0360-3016(02)03037-7.
21. Slack FJ, Weidhaas JB. MicroRNA in cancer prognosis. N Engl J Med 2008; 359:2720-2; PMID:19092157; http://dx.doi.org/10.1056/NEJMe0808667.
22. Russell J, Wheldon TE, Stanton P. A radio-resistant variant derived from a human neuroblastoma cell line is less prone to radiation-induced apoptosis. Cancer Res 1995; 55:4915-21; PMID:7585530.
23. Guo C, Pan ZG, Li DJ, Yun JP, Zheng MZ, Hu ZY, et al. The expression of p63 is associated with the differential stage in nasopharyngeal carcinoma and EBV infection. J Transl Med 2006; 4:23; PMID:16729897; http://dx.doi.org/10. 1186/1479-5876-4-23.
24. Li HF, Kim JS, Waldman T. Radiation-induced Akt activation modulates radioresistance in human glioblastoma cells. Radiat Oncol 2009; 4:43; PMID:19828040; http://dx.doi.org/10.1186/1748-717X-4-43.
25. Steelman LS, Navolanic P, Chappell WH, Abrams SL, Wong EW, Martelli AM, et al. Involvement of Akt and mTOR in chemotherapeutic- and hormonal-based drug resistance and response to radiation in breast cancer cells. Cell Cycle 2011; 10:3003-15; PMID:21869603; http://dx.doi.org/10.4161/cc.10.17.17119.
26. Chappell WH, Steelman LS, Long JM, Kempf RC, Abrams SL, Franklin RA, et al. Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health. Oncotarget 2011; 2:135-64; PMID:21411864.
27. Wu H, Zhu S, Mo YY. Suppression of cell growth and invasion by miR-205 in breast cancer. Cell Res 2009; 19:439-48; PMID:19238171; http://dx.doi. org/10.1038/cr.2009.18.
28. Gregory PA, Bert AG, Paterson EL, Barry SC, Tsykin A, Farshid G, et al. The miR-200 family and miR- 205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol 2008; 10:593- 601; PMID:18376396; http://dx.doi.org/10.1038/ ncb1722.
29. Gandellini P, Folini M, Longoni N, Pennati M, Binda M, Colecchia M, et al. miR-205 Exerts tumor-suppressive functions in human prostate through downregulation of protein kinase Cepsilon. Cancer Res 2009; 69:2287-95; PMID:19244118; http://dx.doi. org/10.1158/0008-5472.CAN-08-2894.
30. Song H, Bu G. MicroRNA-205 inhibits tumor cell migration through downregulating the expression of the LDL receptor-related protein 1. Biochem Biophys Res Commun 2009; 388:400-5; PMID:19665999; http://dx.doi.org/10.1016/j. bbrc.2009.08.020.
31. Iorio MV, Visone R, Di Leva G, Donati V, Petrocca F, Casalini P, et al. MicroRNA signatures in human ovarian cancer. Cancer Res 2007; 67:8699-707; PMID:17875710; http://dx.doi.org/10.1158/0008-5472.CAN-07-1936.
32. Gregory PA, Bracken CP, Bert AG, Goodall GJ. MicroRNAs as regulators of epithelial-mesenchymal transition. Cell Cycle 2008; 7:3112-8; PMID:18927505; http://dx.doi.org/10.4161/ cc.7.20.6851.
33. Kurrey NK, Jalgaonkar SP, Joglekar AV, Ghanate AD, Chaskar PD, Doiphode RY, et al. Snail and slug mediate radioresistance and chemoresistance by antagonizing p53-mediated apoptosis and acquiring a stem-like phenotype in ovarian cancer cells. Stem Cells 2009; 27:2059-68; PMID:19544473; http://dx.doi. org/10.1002/stem.154.
34. Stambolic V, MacPherson D, Sas D, Lin Y, Snow B, Jang Y, et al. Regulation of PTEN transcription by p53. Mol Cell 2001; 8:317-25; PMID:11545734; http:// dx.doi.org/10.1016/S1097-2765(01)00323-9.
35. Su CH, Zhao R, Zhang F, Qu C, Chen B, Feng YH, et al. 14-3-3sigma exerts tumor-suppressor activity mediated by regulation of COP1 stability. Cancer Res 2011; 71:884-94; PMID:21135113; http://dx.doi. org/10.1158/0008-5472.CAN-10- 2518.
36. Qin L, Zhang X, Zhang L, Feng Y, Weng GX, Li MZ, et al. Downregulation of BMI-1 enhances 5-fluorouracil- induced apoptosis in nasopharyngeal carcinoma cells. Biochem Biophys Res Commun 2008; 371:531- 5; PMID:18452707; http://dx.doi.org/10.1016/j. bbrc.2008.04.117.